


Re-evaluating the Incidence of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Julian Borchardt, Joseph R. Berger



PII: S2211-0348(16)30024-4
DOI: <http://dx.doi.org/10.1016/j.msard.2016.03.005>
Reference: MSARD370

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 23 December 2015
Accepted date: 14 March 2016

Cite this article as: Julian Borchardt and Joseph R. Berger, Re-evaluating the Incidence of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy, *Multiple Sclerosis and Related Disorders* <http://dx.doi.org/10.1016/j.msard.2016.03.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Re-evaluating the Incidence of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Julian Borchardt^{a*}, Joseph R. Berger^b

^aan independent statistical consultant in Germany.

^bThe Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Corresponding author. borchardt@gmx.de.

Abstract

Objective

To estimate the prospective risk of developing PML during therapy with natalizumab in JCV-seropositive patients.

Methods

We analyzed postmarketing data about the incidence of PML on natalizumab and quantified the risks by either applying the Kaplan-Meier estimator or, where this was not possible due to the unavailability of the respective raw data, using formulae yielding very similar figures.

Results

In JCV-seropositive patients with prior immunosuppressive treatment, the PML risk for months 25–48 of natalizumab therapy is about 19.5 per thousand. Without previous exposure to immunosuppressants, the risk during months 25–48 is approximately 7.4 per thousand, and for months 49–72, it is approximately 10.8 per thousand. If one additionally assumes that the JCV index is in the range 0.9–1.5, then the incidence for months 49–72 is around 6.2 per thousand in comparison to 17.0 per thousand when the JCV index exceeds 1.5.

Conclusions

Biogen's statistics concerning the risk of PML on natalizumab treatment, while in principle helpful, underestimate the true incidence systematically and significantly. Realistic estimates of the longterm risk are nearly double those previously published, with some patient groups carrying a risk that is almost nine times higher. Fortunately, a refined risk-stratification algorithm with the incorporation of such measures as L-selectin and CSF lipid-specific antibodies has the potential to make natalizumab a considerably safer drug.

Download English Version:

<https://daneshyari.com/en/article/5912300>

Download Persian Version:

<https://daneshyari.com/article/5912300>

[Daneshyari.com](https://daneshyari.com)